Suzanne Rosenberg, Ph.D. Professor and
Robert and Jane Meyerhoff Chair of Biochemistry
Department:
Biological Sciences, UMBC
UMGCC Research Program:
Hormone Responsive Cancers Program Tumor Immunology and Immunotherapy
Education/Training:
College Degree:
A.B., Barnard College/Columbia University
Post Doctoral
Degree:
Ph.D., California Institute of Technology (Caltech)
Fellowship:
Post-Doctoral Fellow at Johns Hopkins
Contact
Information:
Mailing Address:
Dept. Biological Sciences
UMBC
1000 Hilltop Circle
Baltimore, MD 21250
Email:
srosenbe@umbc.edu
Phone:
410-455-2237
Fax:
410-455-3875
Research Interests:
Tumor Immunology; Processing and Presentation of Tumor Antigens; Activation of Tumor-specific CD4+ T lymphocytes; Tumor-induced immune suppression; Cancer Vaccines
For More Information:
See Dr. Rosenberg's Laboratory for Mouse and Human Cancer Immunology and Immunotherapy Web site: http://mhc.umbc.edu/.
Publications:
Dissanayake, S. K., J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg, 2004. Activation of tumor-specific CD4+ T lymphocytes by MHC class II tumor cell vaccines: A novel cell-based immunotherapy. Cancer Res. 64:1867-1874.
Danna, E., P. Sinha, M. Gilbert, B. Pulaski, and S. Ostrand-Rosenberg, 2004. Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease. Cancer Res. 64:2205-2211.
Dolan, B., T. Phelan, T. Phelan, D. Ilkovitch, L. Qi, W. Wade, T. Laufer, and S. Ostrand-Rosenberg, 2004. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines. J. Immunol. 172:907-914.
Ilkovitch, D. and S. Ostrand-Rosenberg, 2004. MHC class II and CD80 tumor cell-based vaccines are potent activators of naive type 1 CD4+ T lymphocytes provided they do not co-express invariant chain, Cancer Immunol. Immunother., in press.
Ostrand-Rosenberg, S., P. Sinha, V. Clements, S. Dissanayake, S. Miller, C. Davis, and E. Danna, 2004. Signal transducer and activator of transcription 6 (Stat6) and CD1: Inhibitors immunosurveillance against primary tumors and metastatic disease. Canc. Immuol. Immunother. 53:86-91.
Ostrand-Rosenberg, S. 2004. Animal models of tumor immunity, immunotherapy, and cancer vaccines. Curr. Opin. Immunol. 16:143-150.
Pulaski, B., M. Smyth, and S. Ostrand-Rosenberg, 2002. Interferon-×-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Canc. Res. 62: 4406-4412.
Ostrand-Rosenberg, S., V. Clements. M. Terabe, J. Park, J. Berzofsky, 2002. Resistance to metastatic disease in STAT6-deficient mice requires hematopoietic and nonhematopoietic cells and is IFN-×-dependent. J. Immunol., 169:5796-5804.
Qi, L., J. Rojas, and S. Ostrand-Rosenberg, 2000. Tumor cells present MHC class II restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol., 165:5451-5461.
Ostrand-Rosenberg, S., M. Grusby, and V. Clements, 2000. Cutting Edge: STAT6 knockout mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol., 165:6015-6019.
